Trial Profile
A phase 1b, single-blind study of the safety, tolerability, pharmacokinetics and pharmacodynamic activity of three separate dose levels of very low dose-glucagon administered subcutaneously overnight for 6, 9 or 12 hours in subjects with type 1 diabetes mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Glucagon (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors DiObex
- 30 Sep 2006 New trial record.